Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJMN1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 3	NOV 26	MARPAT enhanced with FSORT command
NEWS 4	NOV 26	CHEMSAFE now available on STN Easy
NEWS 5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS 6	DEC 01	ChemPort single article sales feature unavailable
NEWS 7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS 9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 14	FEB 10	COMPENDEX reloaded and enhanced
NEWS 15	FEB 11	WTEXTILES reloaded and enhanced
NEWS 16	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,

AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:11:36 ON 08 MAR 2009

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.66	0.66

FILE 'REGISTRY' ENTERED AT 17:13:36 ON 08 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 MAR 2009 HIGHEST RN 1116745-20-0
DICTIONARY FILE UPDATES: 6 MAR 2009 HIGHEST RN 1116745-20-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10526507\formula I 3_8_09.str





chain nodes :
8 9 10 11 12 13 15 22
ring nodes :
1 2 3 4 5 6 16 17 18 19 20
chain bonds :
5-8 8-9 9-10 10-11 11-12 11-13 12-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-20 17-18 18-19 19-20
exact/norm bonds :
5-8 8-9 9-10 10-11 11-12 11-13 12-15 16-17 16-20 17-18 18-19 19-20
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 16 :

G1:H,Cb,Ak

G2:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom
22:Atom 23:Atom
Generic attributes :
22:
Saturation : Unsaturated

```
L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1              STR
```




```
G1 H,Cb,Ak
G2 O,S


Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 17:14:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    35989 TO ITERATE

  5.6% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       708437 TO   731123
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 17:15:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   720424 TO ITERATE

 90.3% PROCESSED   650410 ITERATIONS                              24 ANSWERS

 96.2% PROCESSED   693179 ITERATIONS                              24 ANSWERS

100.0% PROCESSED   720424 ITERATIONS                              24 ANSWERS
SEARCH TIME: 00.00.40

L3           24 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               187.32     187.98
```

FILE 'CAPLUS' ENTERED AT 17:15:47 ON 08 MAR 2009

FILE COVERS 1907 - 8 Mar 2009 VOL 150 ISS 11
FILE LAST UPDATED: 6 Mar 2009 (20090306/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 15 L3

=> d ibib 1-5

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:845716 CAPLUS
DOCUMENT NUMBER: 145:293345
TITLE: Preparation of N-acyl-amino acid derivatives for controlling function of GPR34 receptor as antagonists or inverse agonists
INVENTOR(S): Ito, Fumio; Kimura, Eiji; Imai, Tomomi; Mori, Masaaki; Aramaki, Yoshio; Kohara, Yasuhisa; Sugo, Tsukasa; Hayase, Yoji; Kobayashi, Hiromi; Ogi, Kazuhiro
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 597pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006088246	A1	20060824	WO 2006-JP303357	20060217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1849465	A1	20071031	EP 2006-714496	20060217
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			JP 2005-41775	A 20050218
			JP 2005-315146	A 20051028
			WO 2006-JP303357	W 20060217

OTHER SOURCE(S): MARPAT 145:293345
REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1259559 CAPLUS
DOCUMENT NUMBER: 144:22935
TITLE: Preparation of substituted pyrimidines as inhibitors of bacterial type III protein secretion systems
INVENTOR(S): Li, Xiaobing
PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Belg.
SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005113514	A2	20051201	WO 2005-US16106	20050506
WO 2005113514	A3	20060119		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050282824	A1	20051222	US 2005-124226	20050506
PRIORITY APPLN. INFO.:			US 2004-568850P	P 20040507

OTHER SOURCE(S): CASREACT 144:22935; MARPAT 144:22935
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1259524 CAPLUS
DOCUMENT NUMBER: 144:22910
TITLE: Preparation of azole carboxamides as inhibitors of bacterial type III protein secretion systems
INVENTOR(S): Li, Xiaobing; Murray, William V.; Macielag, Mark J.; Guan, Qunying
PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Belg.
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005113522	A1	20051201	WO 2005-US16105	20050506
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050272784	A1	20051208	US 2005-123977	20050506
PRIORITY APPLN. INFO.:			US 2004-568851P	P 20040507

OTHER SOURCE(S): CASREACT 144:22910; MARPAT 144:22910
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:903957 CAPLUS
DOCUMENT NUMBER: 143:258130
TITLE: Reactive mesogenic charge transport compounds
INVENTOR(S): Heeney, Martin; Zhang, Weimin; Tierney, Steven; Sparrowe, David; Shkunov, Maxim; Mcculloch, Iain
PATENT ASSIGNEE(S): UK
SOURCE: U.S. Pat. Appl. Publ., 31 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050184274	A1	20050825	US 2005-66007	20050225
WO 2005080369	A2	20050901	WO 2005-EP911	20050131
WO 2005080369	A3	20051006		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1725541	A2	20061129	EP 2005-701266	20050131
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1922167	A	20070228	CN 2005-80006042	20050131
JP 2007533659	T	20071122	JP 2007-500084	20050131
EP 1876177	A2	20080109	EP 2007-19781	20050131
EP 1876177	A3	20080402		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
EP 1903036	A1	20080326	EP 2007-19782	20050131
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
KR 2006135783	A	20061229	KR 2006-717278	20060825
PRIORITY APPLN. INFO.:			US 2004-547068P	P 20040225
			EP 2004-5797	A 20040311
			EP 2005-701266	A3 20050131
			WO 2005-EP911	W 20050131

L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:220326 CAPLUS
DOCUMENT NUMBER: 140:270727
TITLE: Preparation of furan derivatives for treatment of abnormal lipid metabolism, arteriosclerosis, and diabetes
INVENTOR(S): Hamamura, Kazumasa; Sasaki, Shigekazu; Amano, Yuichiro; Sakamoto, Junichi; Fukatsu, Kohji
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 325 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022551	A1	20040318	WO 2003-JP11308	20030904
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2497901	A1	20040318	CA 2003-2497901	20030904
AU 2003261935	A1	20040329	AU 2003-261935	20030904
EP 1535915	A1	20050601	EP 2003-794233	20030904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005035966	A	20050210	JP 2003-314293	20030905
US 20060100261	A1	20060511	US 2005-526507	20050929

PRIORITY APPLN. INFO.: JP 2002-261873 A 20020906
JP 2003-112541 A 20030627
WO 2003-JP11308 W 20030904

OTHER SOURCE(S): MARPAT 140:270727
GI

L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



I



II

AB The title compds. I [wherein R = (un)substituted hydrocarbyl or heterocyclyl; p = 0-2; R1 = H or (un)substituted hydrocarbyl; R2 = (un)substituted aryl; ring A = (un)substituted aromatic ring; X1 = O or S; X2 = a bond, O, S, SO, or SO2; Y = a bond, O, S, SO, SO2, CO, (un)substituted CONH, or NHCO; M1-M3 = independently a bond or (un)substituted aliphatic hydrocarbyl; M4 = (un)substituted aliphatic hydrocarbyl; with exclusions], or prodrugs, or pharmaceutically acceptable salts thereof are prepared For example, the compound II was prepared in a multi-step synthesis. II exhibited EC50 of 0.10 μM towards human G protein-coupled receptors (GPR40). I are useful for the treatment of abnormal lipid metabolism, arteriosclerotic diseases, secondary diseases, diabetes, etc. (no data). Formulations containing I as an active ingredient were also described.

IT 672928-49-3P 672929-08-7P 672929-09-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of furan derivs. for treatment of abnormal lipid metabolism, arteriosclerosis, and diabetes)

RN 672928-49-3 CAPLUS
CN Acetic acid, 2-[[3-[[5-(4-fluorophenyl)-2-methyl-3-furanyl]methoxy]phenyl]methoxy]- (CA INDEX NAME)

L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 672929-08-7 CAPLUS
CN Propanoic acid, 2-methyl-2-[[3-[[2-methyl-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methoxy]phenyl]methoxy]- (CA INDEX NAME)



RN 672929-09-8 CAPLUS
CN Propanoic acid, 2-[[3-[[5-(4-fluorophenyl)-2-methyl-3-furanyl]methoxy]phenyl]methoxy]-2-methyl- (CA INDEX NAME)

L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:696857 CAPLUS
DOCUMENT NUMBER: 139:230479
TITLE: Preparation of [4-(1,1'-biphenyl-2-ylcarbonylamino or benzoylamino)phenyl]acetic acid esters as microsomal triglyceride transfer protein (MTP) inhibitors
INVENTOR(S): Hagiwara, Atsushi; Oe, Yasuhiro; Odani, Naoya; Watanabe, Shizue; Ikenogami, Taku; Kawai, Takashi; Madono, Kenya; Taniguchi, Toshio
PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan
SOURCE: PCT Int. Appl., 561 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072532	A1	20030904	WO 2003-JP2398	20030228
W: AE, AG, AL, AM, AU, AZ, BA, BB, BR, BY, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, ID, IL, IN, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, RU, SC, SG, TJ, TM, TN, TT, UA, US, UZ, VC, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2460682	A1	20030904	CA 2003-2460682	20030228
AU 2003211617	A1	20030909	AU 2003-211617	20030228
AU 2003211617	B2	20060202		
JP 2003321424	A	20031111	JP 2003-53869	20030228
JP 3662566	B2	20050622		
BR 2003006292	A	20040824	BR 2003-6292	20030228
EP 1479666	A1	20041124	EP 2003-743078	20030228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1630629	A	20050622	CN 2003-804734	20030228
ZA 2005002495	A	20050920	ZA 2005-2495	20030228
ZA 2005002496	A	20051012	ZA 2005-2496	20030228
NZ 531890	A	20060224	NZ 2003-531890	20030228
RU 2293721	C2	20070220	RU 2004-124370	20030228
CN 1943786	A	20070411	CN 2006-10099709	20030228
NZ 543229	A	20070531	NZ 2003-543229	20030228
NZ 543230	A	20080328	NZ 2003-543230	20030228
MX 2004002602	A	20040811	MX 2004-2602	20040319
MX 2007000397	A	20070330	MX 2007-397	20040319
ZA 2004002275	A	20050423	ZA 2004-2275	20040323
IN 2004KN00460	A	20060324	IN 2004-KN460	20040407
NO 2004001872	A	20040506	NO 2004-1872	20040506
US 20050075367	A1	20050407	US 2004-492831	20041008
JP 2005194281	A	20050721	JP 2005-19579	20050127
JP 2005220132	A	20050818	JP 2005-19739	20050127
JP 2005220133	A	20050818	JP 2005-20179	20050127
AU 2005248950	A1	20060119	AU 2005-248950	20051223

L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

KR 2006053023	A	20060519	KR 2006-707778	20060421
IN 2007KN00581	A	20070706	IN 2007-KN581	20070216

PRIORITY APPLN. INFO.:

JP 2002-53876	A	20020228
AU 2003-211617	A3	20030228
CN 2003-804734	A3	20030228
JP 2003-53869	A3	20030228
NZ 2003-531890	A3	20030228
WO 2003-JP2398	W	20030228
IN 2004-KN460	A3	20040407
KR 2004-707905	A3	20040525
JP 2004-210492	A	20040716
US 2004-598233P	P	20040802

OTHER SOURCE(S): MARPAT 139:230479
GI



I



II

AB The title compds. [I; R1, R2 = H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkoxy, halo-C1-6 alkyl, halo-C1-6 alkoxy, each (un)substituted C6-14 aryl, C7-16 aralkyl, C6-14 aryloxy, C7-16 aryloxy, C7-16 aralkyloxy, C7-15 arylcarbonyl, heterocyclyl, or NH2 C2-7 alkoxycarbonyl, halo, C2-6 alkenyl; the ring A = C6-14 aryl, heterocyclyl, 9-oxofluorenyl, fluorenyl;

L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

X = CO2(CH2)n, each N-(un)substituted CONH(CH2)n or NHCO(CH2)n (wherein n = an integer of 0-3); R3, R4 = H, HO, halo, each (un)substituted C1-6 alkyl, heterocyclyl, or CONH2, C1-6 alkoxy, halo-C1-6 alkyl, C7-16 aralkyloxy, C1-6 acyl; the ring B = phenylene, C5-7 (aza)cycloalkanediyl, indolediyl, benzimidazolediyl, pyridinediyl, pyrimidinediyl, benzocycloalkanedilyl, quinolinediyl, etc.; Alk11, Alk12 = alkanediyl, alkenediyl; n, m = 0-3; D = C1-6 alkyl, C2-6 alkenyl, C2-7 alkoxycarbonyl, NR42COR43 (wherein R42 = H, C1-6 alkyl; R43 = C4-14 aryl, C7-16 aralkyl), etc.; R8, R9 = H, C1-6 alkyl, (un)substituted C6-14 aryl, CONH2, or NH2, succinimid-2-yl, hydroxy-C1-6 alkyl, CO2H or its ester, (CH2)sO2CR20 (wherein R20 = H, C1-6 alkyl, C3-7 cycloalkyl; s = 0-3)] or prodrugs thereof or pharmaceutically acceptable salts of either are prepd. These compds. I electively inhibit microsomal triglyceride transfer protein (MTP) of small intestine, are metabolized in blood or liver, and residual amt. of MTP inhibitors is small enough not to substantially inhibit liver MTP and hence causes no side effects such as a fatty liver. They are useful for prevention or treatment of hyperlipidemia, arteriosclerosis, coronary artery diseases, obesity, diabetes, or hypertension. Thus, 519 mg 4-[(4'-trifluoromethyl-1,1'-biphenyl-2-ylcarbonyl)amino]phenylacetic acid (prepn. given), 317 mg 2-hydroxymethyl-2-phenylmalonic acid diethylamide pg, and 268 mg 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were dissolved in 5 mL CH2Cl2 and stirred at room temp. for 6 h to give, after distn. of the solvent and silica gel chromatog., 725 mg 4-[(4'-trifluoromethyl-1,1'-biphenyl-2-ylcarbonyl)amino]phenylacetic acid 2,2-bis(ethylcarbamoyl)-2-phenylethyl ester (II; R = H). II (R = H) and II (R = Me) inhibited the triglyceride transport between liposomes by MTP with IC50 of 0.6 and 0.39 nM, resp., and the secretion of apolipoprotein B from HepG2 cell with IC50 of 0.65 and 0.46, resp. Pharmaceutical formulations, e.g. a tablet contg. 2-[[2-[4-[(4'-trifluoromethyl-1,1'-biphenyl-2-ylcarbonyl)amino]-3-(pyrrolidinocarbonyl)phenyl]acetoxy]methyl]-2-phenylmalonic acid di-Et ester, were described.

IT 594841-79-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [(biphenylylcarbonylamino or benzoylamino)phenyl]acetic acid esters as microsomal triglyceride transfer protein (MTP) inhibitors for treatment or prevention of diseases)

RN 594841-79-9 CAPLUS
CN Propanedioic acid, 2-phenyl-2-[[[2-[4-[[2-(3-thienyl)benzoyl]amino]phenyl]acetyl]oxy]methyl]-, 1,3-diethyl ester (CA INDEX NAME)



L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:754366 CAPLUS
DOCUMENT NUMBER: 137:279197
TITLE: Preparation of five-membered heterocyclic alkanoic acid derivatives as remedies for diabetes and hyperlipidemia
INVENTOR(S): Momose, Yu; Maekawa, Tsuyoshi; Imoto, Hiroshi; Odaka, Hiroyuki; Kimura, Hiroyuki
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 165 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076959	A1	20021003	WO 2002-JP2741	20020322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002239023	A1	20021008	AU 2002-239023	20020322
JP 2002348281	A	20021204	JP 2002-81621	20020322
EP 1394154	A1	20040303	EP 2002-705433	20020322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040063775	A1	20040401	US 2003-472159	20030922
US 7241785	B2	20070710		

PRIORITY APPLN. INFO.: JP 2001-85572 A 20010323
WO 2002-JP2741 W 20020322

OTHER SOURCE(S): MARPAT 137:279197
GI



I

AB The title compds. I [R1 represents an optionally substituted five-membered heterocyclic group; X represents a bond, etc.; Q represents a C1-20 divalent hydrocarbon group; Y represents a bond, etc.; ring A represents an aromatic ring optionally having one to three substituents; Z represents

L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(CH2)nZ1 (n is an integer of 0 to 8 and Z1 represents a bond, etc.), etc.; ring B represents a five-membered heterocycle optionally having one to three substituents; W represents a C1-20 divalent satd. hydrocarbon group; and R2 represents OH, etc.] are prepd. A process for prepg. I is disclosed. Compds. of this invention at 0.01% in feed given to diabetic mice for 4 days caused 43% to 42% decrease of blood sugar. Formulations are given.
IT 464185-05-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of five-membered heterocyclic alkanoic acid derivs. as remedies
for diabetes and hyperlipidemia)
RN 464185-05-5 CAPLUS
CN Benzenepentanoic acid, γ-[[2-[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]phenyl]acetyl]oxy]-δ-oxo-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 88 THERE ARE 88 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:47829 CAPLUS
DOCUMENT NUMBER: 136:110073
TITLE: Silver halide photographic film containing triazole derivative cyan coupler
INVENTOR(S): Ikesu, Satoru; Oshiyama, Tomohiro; Okubo, Kimihiko
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 39 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002014445	A	20020118	JP 2000-198441	20000630

PRIORITY APPLN. INFO.: JP 2000-198441 20000630

OTHER SOURCE(S): MARPAT 136:110073
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The material contains a cyan coupler I, II, III, IV, or V (R1, R4-5, R7, R9-12 = alkyl, aryl, heterocycle; R2-3 = H, alkyl, aryl, heterocycle; L1 = O, SO , SO2; L2, L4 = O, NR13; R13 = H, alkyl, aryl, heterocycle; L3 = divalent linkage; R6, R8 = substituent; Ar = aryl; X1-5 = H, releasing group in the reaction with developer oxide; n1 = 0-4; n2 = 0-3). The material gives high d. clear cyan images and shows sharp absorption and good resistance to heat and high temperature
IT 389579-00-4
RL: DEV (Device component use); USES (Uses)
(silver halide photog. film containing triazole derivative cyan coupler)
RN 389579-00-4 CAPLUS
CN Benzoic acid, 4-chloro-3-[[[7-(4-chlorophenoxy)-3-(1,1-dioxido-2-thienyl)-1H-pyrazolo[5,1-c]-1,2,4-triazol-6-yl]carbonyl]amino]-, 2-(dodecyloxy)-1-methyl-2-oxoethyl ester (CA INDEX NAME)

L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L4 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:59441 CAPLUS
DOCUMENT NUMBER: 130:261459
TITLE: Three-Dimensional Quantitative Structure-Activity Relationship of Interleukin 1-β Converting Enzyme Inhibitors: A Comparative Molecular Field Analysis Study
AUTHOR(S): Kulkarni, Santosh S.; Kulkarni, Vithal M.
CORPORATE SOURCE: Department of Chemical Technology Pharmaceutical Division, University of Mumbai, Mumbai, 400 019, India
SOURCE: Journal of Medicinal Chemistry (1999), 42(3), 373-380 CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A three-dimensional quant. structure-activity relationship (QSAR) study using the comparative mol. field anal. (CoMFA) method was performed on a series of interleukin 1-β converting enzyme (ICE) inhibitors. The compds. studied have been reported to be time-dependent inhibitors of ICE.

This study was performed using 49 compds., in which the CoMFA models were developed using a training set of 39 compds. All the compds. were modeled using the X-ray crystal structure of tetrapeptide aldehyde inhibitor/ICE complex. The inhibitor compds. were considered both as neutral species and as P1 carboxylate ionized species. Superimpositions were performed using two alignment rules, namely, an alignment of the structures based on RMS fitting of the backbone heavy atoms of each structure to compound 2 and an alignment based on SYBYL QSAR rigid body field fit of the steric and electrostatic fields of the mols. to the fields of compound 2. Use of LUMO energies or ClogP as addnl. descriptors in the QSAR table did not improve the significance of the CoMFA models. Steric and electrostatic fields of the inhibitors were found to be the relevant descriptors for structure-activity relationships. The predictive ability of the CoMFA model was evaluated by using a test set of 10 compds. (r2pred as high as 0.859). Further comparison of the coefficient contour maps with the steric and electrostatic properties of the receptor show a high level of compatibility.

IT 173305-41-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(QSAR of interleukin 1β converting enzyme inhibitors: comparative mol. field anal. study)
RN 173305-41-4 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[[6-oxo-5-[[(phenylmethoxy)carbonyl]amino]-2-(2-thienyl)-1(6H)-pyrimidinyl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Absolute stereochemistry.



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:636190 CAPLUS
DOCUMENT NUMBER: 127:307394
ORIGINAL REFERENCE NO.: 127:60125a,60128a
TITLE: Preparation of N-(6-oxo-1-pyrimidinylacetyl)aspartic acid analogs as interleukin-1β-converting enzyme inhibitors
INVENTOR(S): Dolle, Roland E.; Prouty, Catherine P.; Chaturvedula, Prasad V.; Schmidt, Stanley J.
PATENT ASSIGNEE(S): Sanoft, Fr.
SOURCE: U.S., 12 pp., Cont.-in-part of U.S. Ser. No. 221,712. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5670494	A	19970923	US 1995-559870	19951120
CN 1149292	A	19970507	CN 1995-193258	19950329
CN 1118458	C	20030820		
PT 752987	T	20040331	PT 1995-915448	19950329
CN 1504462	A	20040616	CN 2003-2003145218	19950329
ES 2210289	T3	20040701	ES 1995-915448	19950329
US 6162800	A	20001219	US 1997-877380	19970617
US 20010003750	A1	20010614	US 2000-740623	20001219
US 6407080	B2	20020618		

PRIORITY APPLN. INFO.: US 1994-221712 B2 19940331
US 1995-559870 A1 19951120
US 1997-877380 A3 19970617

OTHER SOURCE(S): MARPAT 127:307394
GI



AB Title compds. [I; R = e.g., CR5(CH2COR6)COR7; R1 = (CR3R4)0-4R20; R2 = H, alkyl, (hetero)aryl, etc.; R3,R4 = H or (ar)alkyl; R5 = H or D; R6 = OR8 or NHOH; R7 = H, CH2F, aroyloxymethyl, heteroaryloxymethyl, etc.; R8 = H or (ar)alkyl; R20 = groups cited for R2, heterocyclyl, etc.] were prepared
Thus, 2,6-Cl2C6H3CO2H was esterified by (S)-Me3cO2CCH2CH(NHCO2CH2PH)COCH2Br and the deprotected product amidated by 5-benzyloxycarbonylamino-6-oxo-2-(4-fluorophenyl)-1,6-dihydropyrimidine-1-acetic acid to give, after saponification, I [R =

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(S)-CH(CH2CO2H)COCH2O2CC6H3Cl2-2,6, R1 = CO2CH2Ph, R2 = C6H4F-4, R3 = R4 = H]. Data for biol. activity of I were given.

IT 173305-41-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(6-oxo-1-pyrimidinylacetyl)aspartic acid analogs as interleukin-1β-converting enzyme inhibitors)
RN 173305-41-4 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[[6-oxo-5-[[(phenylmethoxy)carbonyl]amino]-2-(2-thienyl)-1(6H)-pyrimidinyl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:326451 CAPLUS
DOCUMENT NUMBER: 125:48346
ORIGINAL REFERENCE NO.: 125:9005a,9008a
TITLE: First Examples of Peptidomimetic Inhibitors of Interleukin-1β Converting Enzyme
AUTHOR(S): Dolle, Roland E.; Prouty, Catherine P.; Prasad, C. V. C.; Cook, Ewell; Saha, Ashis; Ross, Tina Morgan; Salvino, Joseph M.; Helaszek, Carla T.; Ator, Mark A.
CORPORATE SOURCE: Sanofi Winthrop Inc., Collegeville, PA, 19426, USA
SOURCE: Journal of Medicinal Chemistry (1996), 39(13), 2438-2440
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 125:48346

AB The pyrimidinone-based peptidomimetics are potent time-dependent inactivators of interleukin-1β converting enzyme ((kobs/[I]) = 30,000 to 268,000 M-1 s-1). These agents retain the P1 aspartic acid residue and critical hydrogen-bonding functionality (P1 and P3 NH), structural elements previously shown to be required for potent enzyme inhibition by peptide inhibitors. A modular approach to the synthesis of the pyrimidinone-based peptidomimetics is also described.

IT 177742-23-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of peptidomimetic inhibitors of interleukin-1β converting enzyme in relation to structure)

RN 177742-23-3 CAPLUS
CN Benzoic acid, 2,4-dichloro-, 4-carboxy-2-oxo-3-[[[6-oxo-5-[[(phenylmethoxy)carbonyl]amino]-2-(2-thienyl)-1(6H)-pyrimidinyl]acetyl]amino]butyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:278112 CAPLUS
DOCUMENT NUMBER: 125:34013
ORIGINAL REFERENCE NO.: 125:6661a,6664a
TITLE: Synthesis of mimics to thymidine and 5-(2"-thienyl)-2'-deoxyuridine triphosphates
AUTHOR(S): Wellmar, Ulf; Hoernfeldt, Anna-Britta; Gronowitz, Salo; Johansson, Nils Gunnar
CORPORATE SOURCE: Chemical Center, Organic Chemistry 1, Lund, S-221 00, Swed.
SOURCE: Nucleosides & Nucleotides (1996), 15(5), 1059-1076
CODEN: NUNUD5; ISSN: 0732-8311
PUBLISHER: Dekker
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Dicarboxylic acid 5'-monoesters of thymidine and 5-(2-thienyl)-2"-deoxyuridine I [R = Me, 2-thienyl; X = (CH2)n, 1,4-cyclohexandiyl; n = 3-5] have been synthesized and evaluated as triphosphate mimics. The glutarate and adipate derivs. can assume conformations fitting the triphosphate, and I [R = 2-thienyl, X = (CH2)3, (CH2)4] were the ones having overall best inhibitory activities against DNA pol α and HIV-1 RT.

IT 177779-38-3P 177779-39-4P 177779-40-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and virucidal activity of thymine and thienyldeoxyuridine monoesters of alkanedicarboxylic acids)

RN 177779-38-3 CAPLUS
CN Uridine, 2'-deoxy-5-(2-thienyl)-, 5'-(phenylmethyl pentanedioate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 177779-39-4 CAPLUS
CN Uridine, 2'-deoxy-5-(2-thienyl)-, 5'-(phenylmethyl hexanedioate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177779-40-7 CAPLUS
CN Uridine, 2'-deoxy-5-(2-thienyl)-, 5'-(phenylmethyl heptanedioate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:996306 CAPLUS
DOCUMENT NUMBER: 124:146843
ORIGINAL REFERENCE NO.: 124:27341a,27344a
TITLE: Preparation of N-(pyrimidinyl)aspartic acid α-substituted Me ketones and aspartic acid aldehydes as interleukin-1β protease inhibitors
INVENTOR(S): Dolle, Roland E.; Prouty, Catherine P.; Chaturvedula, Prasad V.; Schmidt, Stanley J.
PATENT ASSIGNEE(S): Sanofi Winthrop, Inc., USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9526958	A1	19951012	WO 1995-US3909	19950329
W: AU, CA, CN, FI, HU, JP, MX, NO, NZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2186511	A1	19951012	CA 1995-2186511	19950329
CA 2186511	C	20090210		
AU 9522323	A	19951023	AU 1995-22323	19950329
AU 703451	B2	19990325		
EP 752987	A1	19970115	EP 1995-915448	19950329
EP 752987	B1	20031112		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1149292	A	19970507	CN 1995-193258	19950329
CN 1118458	C	20030820		
HU 75715	A2	19970528	HU 1996-2664	19950329
HU 224731	B1	20060130		
JP 09511249	T	19971111	JP 1995-525821	19950329
JP 3703836	B2	20051005		
NZ 283876	A	20010330	NZ 1995-283876	19950329
AT 254111	T	20031115	AT 1995-915448	19950329
PT 752987	T	20040331	PT 1995-915448	19950329
CN 1504462	A	20040616	CN 2003-2003145218	19950329
ES 2210289	T3	20040701	ES 1995-915448	19950329
NO 9604058	A	19960926	NO 1996-4058	19960926
NO 308603	B1	20001002		
FI 9603897	A	19960927	FI 1996-3897	19960927
FI 112943	B1	20040213		
HK 1012623	A1	20050114	HK 1998-113788	19981216

PRIORITY APPLN. INFO.: US 1994-221712 A 19940331
WO 1995-US3909 W 19950329

OTHER SOURCE(S): MARPAT 124:146843
GI

L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



I

AB The title compds. [I; R1 = organic residue, etc.; R2 = H, (un)substituted alkyl, etc; R3, R4 = H, alkyl, aralkyl; Y = (un)substituted 2-succinic acid residue, (un)substituted furanyl, etc.], which are inhibitors of interleukin 1β-converting enzyme (e.g., IC50's ≥10 μM), useful as antiinflammatories (no data) and for the treatment of immune diseases (no data), are prepared Thus, N-[2-[5-benzyloxycarbonylamino-6-oxo-2-(4-fluorophenyl)-1,6-dihydro-1-pyrimidinyl]acetoyl]-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone was prepared from N-benzyloxycarbonyl-L-aspartic acid in 4 steps.
IT 173305-41-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(pyrimidinyl)aspartic acid α-substituted Me ketones and aspartic acid aldehydes as interleukin-1β protease inhibitors)
RN 173305-41-4 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[[6-oxo-5-[[(phenylmethoxy)carbonyl]amino]-2-(2-thienyl)-1(6H)-pyrimidinyl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1972:551931 CAPLUS
DOCUMENT NUMBER: 77:151931
ORIGINAL REFERENCE NO.: 77:24975a,24978a
TITLE: Phenylthienyl and phenylfuryl malonic acid derivatives
INVENTOR(S): O'Mant, Derrick Michael
PATENT ASSIGNEE(S): Imperial Chemical Industries Ltd.
SOURCE: U.S., 4 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3691202	A	19720912	US 1970-53005	19700707
CH 518275	A	19720131	CH 1969-518275	19690415
CH 518276	A	19720131	CH 1969-518276	19690415
CH 542197	A	19731115	CH 1971-13516	19690415
CS 160105	B2	19750228	CS 1969-4768	19690415
CS 160102	B2	19750228	CS 1969-8126	19690415
CS 160103	B2	19750228	CS 1969-8127	19690415
AT 287686	B	19710210	AT 1969-11444	19690416
AT 288367	B	19710310	AT 1969-11445	19690416
SU 464109	A3	19750315	SU 1969-1822415	19690416
JP 51006142	B	19760225	JP 1973-72141	19730626
JP 51006143	B	19760225	JP 1973-72142	19730626
JP 51006145	B	19760225	JP 1973-72145	19730626
US 3960893	A	19760601	US 1973-374782	19730628

PRIORITY APPLN. INFO.: GB 1968-50788 A 19681025
GB 1969-58666 A 19681210
GB 1969-17895 A 19690317
GB 1968-17895 A 19680416
GB 1968-58666 A 19681210
US 1969-812358 A3 19690401
US 1970-53007 A1 19700707

GI For diagram(s), see printed CA Issue.
AB Thienyl-malonates I (R = Me, PhCH2; R1 = H, Me) and furylmalonates II (R = H, Me) were prepared by treating the Na derivs. of thienyl-and furylacetates with (MeO)2CO followed by methylation with MeI and/or transesterification with PhCH2OH. I and II have antiinflammatory, hypocholesterolemic, analgesic, and antipyretic activity.
IT 24675-43-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 24675-43-2 CAPLUS
CN Propanedioic acid, 2-[5-(4-chlorophenyl)-2-thienyl]-, 1,3-bis(phenylmethyl) ester (CA INDEX NAME)

L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1970:31599 CAPLUS
DOCUMENT NUMBER: 72:31599
ORIGINAL REFERENCE NO.: 72:5769a,5772a
TITLE: Antiinflammatory furans and thiophenes
INVENTOR(S): O'Mant, Derrick M.
PATENT ASSIGNEE(S): Imperial Chemical Industries Ltd.
SOURCE: Ger. Offen., 44 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1919381	A	19691023	DE 1969-1919381	19690416
DE 1919381	B2	19740516		
DE 1919381	C3	19750206		
GB 1226981	A	19710331	GB 1968-17895	19680416
PL 80177	B1	19750830	PL 1969-132724	19690402
BE 731549	A	19691015	BE 1969-731549	19690415
CH 515231	A	19711115	CH 1969-515231	19690415
CH 518275	A	19720131	CH 1969-518275	19690415
CH 518276	A	19720131	CH 1969-518276	19690415
CH 518277	A	19720131	CH 1969-518277	19690415
CH 542197	A	19731115	CH 1971-13516	19690415
SE 366038	B	19740408	SE 1969-5290	19690415
CH 553177	A	19740830	CH 1971-13515	19690415
CS 160101	B2	19750228	CS 1969-2676	19690415
CS 160105	B2	19750228	CS 1969-4768	19690415
CS 160102	B2	19750228	CS 1969-8126	19690415
CS 160103	B2	19750228	CS 1969-8127	19690415
CS 160104	B2	19750228	CS 1969-8128	19690415
NL 6905846	A	19691020	NL 1969-5846	19690416
FR 2007466	A5	19700113	FR 1969-11873	19690416
AT 285594	B	19701110	AT 1969-3668	19690416
AT 287686	B	19710210	AT 1969-11444	19690416
AT 288367	B	19710310	AT 1969-11445	19690416
AT 288368	B	19710310	AT 1969-11446	19690416
SU 419027	A3	19740305	SU 1969-1324701	19690416
JP 49013789	B	19740403	JP 1969-29607	19690416
JP 51006142	B	19760225	JP 1973-72141	19730626
JP 51006143	B	19760225	JP 1973-72142	19730626
JP 51006144	B	19760225	JP 1973-72144	19730626
JP 51006145	B	19760225	JP 1973-72145	19730626
US 3960893	A	19760601	US 1973-374782	19730628

PRIORITY APPLN. INFO.: GB 1968-17895 A 19680416
GB 1968-50788 A 19681025
GB 1968-58666 A 19681210
US 1969-812358 A3 19690401

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
US 1970-53007 A1 19700707

GI For diagram(s), see printed CA Issue.
AB The preparation of novel thiophene (I, II) and furan derivs. (III, IV) with antiinflammatory, hypocholesteremic, anodynic, and antipyretic properties is described. Thus, a mixture of 3 g I (R = CH2CN) [prepared from I (R = CHO), m. 82-3°, via I (R = CH2OH), m. 125-30°, and I (R = CH2Cl), m. 81.5-3.5°], 85 ml EtOH, 1 ml H2O, and 30 ml concentrated H2SO4 was refluxed 17 hr, to give I (R = CH2CO2Et), m. 66-8° (petroleum ether). Similarly were prepared the following derivs. (type of compound, R, and m.p. given): II, CO2Et, 44.5-5.5°; II, CO2H, 185-7°; II, COCl, 77-8°; II, CH2CO2H, 117.5-19.5°; I, (CH2)2CN, 74-5°; I, (CH2)2CO2H, 150-1°; I, CH2CO2Me, 78-80°; I, CH(CO2Me)2, 74-5°; I, CMe(CO2Me)2, 70°; III, CH2CO2Me, 64-6°; III, CH(CO2Me)2, 58-9°; III, CMe(CO2Me)2, 50-4°; I.0.5H2O, CH2CO2H, 140-3°; I, piperidinocar-bonylmethyl, 74-6°; I, CH2CO2Bu, 34-5°; I, CH2CO2CH2Ph, 71-2°; I, CH(CO2CH2Ph)2, 94°; I, CH2CO2Ph, 101-3°; I, CH2CONH2, 209-10°; I, CH2CONHNH2, 166-8°; I, CH2CONH(CH2)2NEt2, 101-3°; I, CMe2CO2H, 146-8°; IV, CO2Et, 73-5°; IV, CH2OH, 140-1°; IV, CH2Cl, 82-4°; IV, CH2CN, ; IV, CH2CO2Me, <35°; and also α-[4-bromo-5-(p-chlorophenyl)-2-thienyl]acetic acid, m. 136-7°.
IT 24675-43-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 24675-43-2 CAPLUS
CN Propanedioic acid, 2-[5-(4-chlorophenyl)-2-thienyl]-, 1,3-bis(phenylmethyl) ester (CA INDEX NAME)